

HEPATIC AND BILIARY AGENTS PRIOR AUTHORIZATION FORM (form effective 1/6/2025)

FAX this completed form to (844) 205-3386

OR Mail requests to: Pharmacy Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720 OR Prior authorization may be completed at https://www.covermymeds.com/main/prior-authorization-forms/

Prior authorization guidelines for **Hepatic and Biliary Agents** and **Quantity Limits/Daily Dose Limits** are available on the PA Health & Wellness website at https://www.pahealthwellness.com/providers/pharmacy.html

Prescriber name:

New requestRenewal request	l otal pages:			
Name of office contact:		Specialty:		
Contact's phone number:		NPI: State license #:		e #:
LTC facility contact/phone:		Street address:		
Member name:		City/state/zip:		
Member ID#:	DOB:	Phone:	Fax:	
	CLINICAL IN	 IFORMATION	1	
Drug requested:			Strength:	
Dose/directions:			Quantity:	Refills:
Diagnosis (<u>submit documentation</u>):			Dx code (<u>required</u>):	
•		y to the member and this nit documentation for eac	•	
	INITIAL	requests		
For Cholbam (cholic acid): Cholbam (cholic acid) is prescrib Medical history and lab test result spectrometry, neurologic exam)	•	•	•	ing mass
2. For Ocaliva (obeticholic acid): Ocaliva (obeticholic acid) is present of the	ts support the member's divided by of the following contraind rior decompensation event as, persistent thrombocytop mally titrated doses of urso peticholic acid) in combinate	iagnosis (eg, alkaline phosications to Ocaliva (obetich, compensated cirrhosis with enia), or complete biliary of deoxycholic acid (UDCA, ution with ursodeoxycholic acid	phatase, antimitochor nolic acid): decompens th evidence of portal h bstruction ursodiol): cid (UDCA, ursodiol),	sated cirrhosis nypertension (eg,



3.	For a PPAR agonist (e.g., Iqirvo [elafibranor], Livdelzi [seladelpar]):
	☐The requested drug is prescribed by or in consultation with a hepatologist or gastroenterologist
	Medical history and lab test results support the member's diagnosis (eg, alkaline phosphatase, antimitochondrial antibodies, histologic evaluation, imaging)
	The member tried and failed optimally titrated doses of ursodeoxycholic acid (UDCA, ursodiol):
	The member will take the requested drug in combination with ursodeoxycholic acid (UDCA, ursodiol), if tolerated
	The member has a contraindication or history of an intolerance to ursodeoxycholic acid (UDCA,
	ursodiol):
4.	For all other non-preferred Hepatic and Biliary Agents:
	The member tried and failed or has a contraindication or an intolerance to the preferred Hepatic and Biliary Agents approved or
	medically accepted for the member's diagnosis (Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-
	preferred drugs in this class.):
	RENEWAL requests
1.	For Cholbam (cholic acid):
••	Cholbam (cholic acid) is prescribed by or in consultation with a hepatologist or pediatric gastroenterologist
	The member experienced improvement in liver function within the first 3 months of treatment with Cholbam (cholic acid)
	The member does NOT have complete biliary obstruction, persistent clinical or lab indicators of worsening liver function, or
	cholestasis
	- • • · · · · · · · · · · · · · · · · ·
2	For Ocaliva (obaticholic acid):
2.	For Ocaliva (obeticholic acid):
2.	Ocaliva (obeticholic acid) is prescribed by or in consultation with a hepatologist or gastroenterologist
2.	☐ Ocaliva (obeticholic acid) is prescribed by or in consultation with a hepatologist or gastroenterologist ☐ The member has results of recent LFTs showing a positive clinical response to Ocaliva (obeticholic acid)
2.	Ocaliva (obeticholic acid) is prescribed by or in consultation with a hepatologist or gastroenterologist The member has results of recent LFTs showing a positive clinical response to Ocaliva (obeticholic acid) The member does NOT have any of the following contraindications to Ocaliva (obeticholic acid): decompensated cirrhosis
2.	Ocaliva (obeticholic acid) is prescribed by or in consultation with a hepatologist or gastroenterologist The member has results of recent LFTs showing a positive clinical response to Ocaliva (obeticholic acid) The member does NOT have any of the following contraindications to Ocaliva (obeticholic acid): decompensated cirrhosis (Child-Pugh Class B or C) or a prior decompensation event, compensated cirrhosis with evidence of portal hypertension (eg,
2.	Ocaliva (obeticholic acid) is prescribed by or in consultation with a hepatologist or gastroenterologist The member has results of recent LFTs showing a positive clinical response to Ocaliva (obeticholic acid) The member does NOT have any of the following contraindications to Ocaliva (obeticholic acid): decompensated cirrhosis
	Ocaliva (obeticholic acid) is prescribed by or in consultation with a hepatologist or gastroenterologist The member has results of recent LFTs showing a positive clinical response to Ocaliva (obeticholic acid) The member does NOT have any of the following contraindications to Ocaliva (obeticholic acid): decompensated cirrhosis (Child-Pugh Class B or C) or a prior decompensation event, compensated cirrhosis with evidence of portal hypertension (eg, ascites, gastroesophageal varices, persistent thrombocytopenia), or complete biliary obstruction For a PPAR agonist (e.g., Iqirvo [elafibranor], Livdelzi [seladelpar]):
	Ocaliva (obeticholic acid) is prescribed by or in consultation with a hepatologist or gastroenterologist The member has results of recent LFTs showing a positive clinical response to Ocaliva (obeticholic acid) The member does NOT have any of the following contraindications to Ocaliva (obeticholic acid): decompensated cirrhosis (Child-Pugh Class B or C) or a prior decompensation event, compensated cirrhosis with evidence of portal hypertension (eg, ascites, gastroesophageal varices, persistent thrombocytopenia), or complete biliary obstruction For a PPAR agonist (e.g., Iqirvo [elafibranor], Livdelzi [seladelpar]): The requested drug is prescribed by or in consultation with a hepatologist or gastroenterologist
	Ocaliva (obeticholic acid) is prescribed by or in consultation with a hepatologist or gastroenterologist The member has results of recent LFTs showing a positive clinical response to Ocaliva (obeticholic acid) The member does NOT have any of the following contraindications to Ocaliva (obeticholic acid): decompensated cirrhosis (Child-Pugh Class B or C) or a prior decompensation event, compensated cirrhosis with evidence of portal hypertension (eg, ascites, gastroesophageal varices, persistent thrombocytopenia), or complete biliary obstruction For a PPAR agonist (e.g., Iqirvo [elafibranor], Livdelzi [seladelpar]):
	Ocaliva (obeticholic acid) is prescribed by or in consultation with a hepatologist or gastroenterologist The member has results of recent LFTs showing a positive clinical response to Ocaliva (obeticholic acid) The member does NOT have any of the following contraindications to Ocaliva (obeticholic acid): decompensated cirrhosis (Child-Pugh Class B or C) or a prior decompensation event, compensated cirrhosis with evidence of portal hypertension (eg, ascites, gastroesophageal varices, persistent thrombocytopenia), or complete biliary obstruction For a PPAR agonist (e.g., Iqirvo [elafibranor], Livdelzi [seladelpar]): The requested drug is prescribed by or in consultation with a hepatologist or gastroenterologist The member has results of recent LFTs showing a positive clinical response to the requested drug
3.	Ocaliva (obeticholic acid) is prescribed by or in consultation with a hepatologist or gastroenterologist The member has results of recent LFTs showing a positive clinical response to Ocaliva (obeticholic acid) The member does NOT have any of the following contraindications to Ocaliva (obeticholic acid): decompensated cirrhosis (Child-Pugh Class B or C) or a prior decompensation event, compensated cirrhosis with evidence of portal hypertension (eg, ascites, gastroesophageal varices, persistent thrombocytopenia), or complete biliary obstruction For a PPAR agonist (e.g., Iqirvo [elafibranor], Livdelzi [seladelpar]): The requested drug is prescribed by or in consultation with a hepatologist or gastroenterologist The member has results of recent LFTs showing a positive clinical response to the requested drug For all other non-preferred Hepatic and Biliary Agents:
3.	Ocaliva (obeticholic acid) is prescribed by or in consultation with a hepatologist or gastroenterologist ☐ The member has results of recent LFTs showing a positive clinical response to Ocaliva (obeticholic acid) ☐ The member does NOT have any of the following contraindications to Ocaliva (obeticholic acid): decompensated cirrhosis (Child-Pugh Class B or C) or a prior decompensation event, compensated cirrhosis with evidence of portal hypertension (eg, ascites, gastroesophageal varices, persistent thrombocytopenia), or complete biliary obstruction For a PPAR agonist (e.g., Iqirvo [elafibranor], Livdelzi [seladelpar]): ☐ The requested drug is prescribed by or in consultation with a hepatologist or gastroenterologist ☐ The member has results of recent LFTs showing a positive clinical response to the requested drug For all other non-preferred Hepatic and Biliary Agents: ☐ The member tried and failed or has a contraindication or an intolerance to the preferred Hepatic and Biliary Agents approved or
3.	Ocaliva (obeticholic acid) is prescribed by or in consultation with a hepatologist or gastroenterologist The member has results of recent LFTs showing a positive clinical response to Ocaliva (obeticholic acid) The member does NOT have any of the following contraindications to Ocaliva (obeticholic acid): decompensated cirrhosis (Child-Pugh Class B or C) or a prior decompensation event, compensated cirrhosis with evidence of portal hypertension (eg, ascites, gastroesophageal varices, persistent thrombocytopenia), or complete biliary obstruction For a PPAR agonist (e.g., Iqirvo [elafibranor], Livdelzi [seladelpar]): The requested drug is prescribed by or in consultation with a hepatologist or gastroenterologist The member has results of recent LFTs showing a positive clinical response to the requested drug For all other non-preferred Hepatic and Biliary Agents:
3.	□ Ocaliva (obeticholic acid) is prescribed by or in consultation with a hepatologist or gastroenterologist □ The member has results of recent LFTs showing a positive clinical response to Ocaliva (obeticholic acid) □ The member does NOT have any of the following contraindications to Ocaliva (obeticholic acid): decompensated cirrhosis (Child-Pugh Class B or C) or a prior decompensation event, compensated cirrhosis with evidence of portal hypertension (eg, ascites, gastroesophageal varices, persistent thrombocytopenia), or complete biliary obstruction For a PPAR agonist (e.g., Iqirvo [elafibranor], Livdelzi [seladelpar]): □ The requested drug is prescribed by or in consultation with a hepatologist or gastroenterologist □ The member has results of recent LFTs showing a positive clinical response to the requested drug For all other non-preferred Hepatic and Biliary Agents: □ The member tried and failed or has a contraindication or an intolerance to the preferred Hepatic and Biliary Agents approved or medically accepted for the member's diagnosis (Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.): □
4.	□ Ocaliva (obeticholic acid) is prescribed by or in consultation with a hepatologist or gastroenterologist □ The member has results of recent LFTs showing a positive clinical response to Ocaliva (obeticholic acid) □ The member does NOT have any of the following contraindications to Ocaliva (obeticholic acid): decompensated cirrhosis (Child-Pugh Class B or C) or a prior decompensation event, compensated cirrhosis with evidence of portal hypertension (eg, ascites, gastroesophageal varices, persistent thrombocytopenia), or complete biliary obstruction For a PPAR agonist (e.g., Iqirvo [elafibranor], Livdelzi [seladelpar]): □ The requested drug is prescribed by or in consultation with a hepatologist or gastroenterologist □ The member has results of recent LFTs showing a positive clinical response to the requested drug For all other non-preferred Hepatic and Biliary Agents: □ The member tried and failed or has a contraindication or an intolerance to the preferred Hepatic and Biliary Agents approved or medically accepted for the member's diagnosis (Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.): □ PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO 844-205-3386
4.	□ Ocaliva (obeticholic acid) is prescribed by or in consultation with a hepatologist or gastroenterologist □ The member has results of recent LFTs showing a positive clinical response to Ocaliva (obeticholic acid) □ The member does NOT have any of the following contraindications to Ocaliva (obeticholic acid): decompensated cirrhosis (Child-Pugh Class B or C) or a prior decompensation event, compensated cirrhosis with evidence of portal hypertension (eg, ascites, gastroesophageal varices, persistent thrombocytopenia), or complete biliary obstruction For a PPAR agonist (e.g., Iqirvo [elafibranor], Livdelzi [seladelpar]): □ The requested drug is prescribed by or in consultation with a hepatologist or gastroenterologist □ The member has results of recent LFTs showing a positive clinical response to the requested drug For all other non-preferred Hepatic and Biliary Agents: □ The member tried and failed or has a contraindication or an intolerance to the preferred Hepatic and Biliary Agents approved or medically accepted for the member's diagnosis (Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.): □

<u>Confidentiality Notice</u>: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.

Pharmacy Department will respond via fax or phone within 24 hours.

Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)